tada

Thanks for your insights! It gives me far more hope.

It strikes me that in the area of cancers that if a few more months of life can be added and if there is a reasonable safety profile (it seems less demanding than cardio) then a drug has a chance of succeeding.

In the case of the SOC drugs enzalutimide and abiraterone losing there effectiveness the extension provided by zen3694 should have great value as you have pointed out. Therefore, I wonder if BP would be far more likely to move to acquistion at an earlier stage (than say with RVX and apabetalone) just to get control of the trial process and obviously have a potential advantage at an early stage. This, of course, would depend on many factors including the price Don wants, the acquiring companies belief in the scientific evidence to date and competitive compounds.

As I understand it epigenetics has been an area of interest and research in the cancer field for years. Perhaps if Pfizer or another BP senses that zen3694 has a lead in this area they may move quickly.

GLTA

Toinv